Publicacións en colaboración con investigadores/as de University of Parma (5)

2024

  1. Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma

    Nature Communications, Vol. 15, Núm. 1

2022

  1. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)

    Nature Medicine

  2. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

    Nature Medicine, Vol. 28, Núm. 3, pp. 557-567

2017

  1. ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma

    Cancer Cell, Vol. 32, Núm. 1, pp. 88-100.e6

2015

  1. Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome

    Cancer Cell, Vol. 27, Núm. 5, pp. 644-657